Skip to main content
Premium Trial:

Request an Annual Quote

BD Gains Access to University College London Patient Samples for Assay Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson and UCL Business, a subsidiary of University College London, announced this week an agreement that could lead to biomarker assays for ovarian and breast cancers.

The deal gives BD access to UCL's biobanks containing more than 200,000 human patient samples collected in prospective screening clinical trials for the detection and management of epithelial ovarian cancer. BD will use the samples to develop and validate biomarker assays.

A BD spokesman said that the company has not decided yet whether the assays will be developed as molecular tests or immunoassays. He said that decision will depend on "the particular test's indication, the sample type, and the information needed to best advise and manage target patient populations."

Financial and other terms of the agreement were not disclosed.

"The ability to access UCL's samples and work with its leading researchers represents a major step toward BD's goal of developing and commercializing tests that significantly improve the detection and management of" ovarian and breast cancers, said Wayne Brinster, VP and GM of women's health and cancer for BD Diagnostics, in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.